MSB 0.53% 95.5¢ mesoblast limited

Regenexx are competitors. The difference is that they inject the...

  1. 3,703 Posts.
    lightbulb Created with Sketch. 48
    Regenexx are competitors. The difference is that they inject the patient with his own stem cells. This process is not FDA approved. In fact Regenexx are in fighting the FDA, on the basis that it is a surgical procedure and therefore not an FDA issue. So there has not been any trials that prove their assertions about efficacy. In fact you will find very little authoritive unbiased imformation about Regenexx. So they have a vested interest in baggging MSB. Never the less, I would like a clinician to evaluate the article by them.
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
(20min delay)
Last
95.5¢
Change
0.005(0.53%)
Mkt cap ! $1.090B
Open High Low Value Volume
95.0¢ 96.0¢ 93.5¢ $2.477M 2.610M

Buyers (Bids)

No. Vol. Price($)
5 14809 95.0¢
 

Sellers (Offers)

Price($) Vol. No.
95.5¢ 10582 1
View Market Depth
Last trade - 16.10pm 28/08/2024 (20 minute delay) ?
MSB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.